IP Library Granted Patent US 7,510,849
Granted Patent B2
US 7,510,849 · App. 11/040,388 · Granted Mar 31, 2009

OCT based method for diagnosis and therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,510,849
App. No.
11/040,388
Granted
Mar 31, 2009
Kind
B2
Abstract

This invention relates to a method of diagnosing or treating a biological subject, such as a person or animal, comprising the steps of subjecting at least a microsample of the subject's tissue to a physiological perturbation and measuring the response of the microsample to the perturbation using optical coherence tomography (OCT). In an exemplary embodiment, the concentration of glucose in the microsample is perturbed, as by providing the subject with a high glucose drink, and subsequently monitoring at a high sample rate in a microsample by OCT. Pathology, such as diabetes, can be diagnosed by deviation of the concentration vs. time response over several cells (micro-oscillation) from the micro-oscillation in the cells of a healthy subject. Other applications include diagnosing or treating de-hydration and diseases that cause changes in the osmolyte concentrations and thus the osmotic pressure in the cells in tissue.

Claims (18)

1. A method of characterizing a patient's blood glucose concentrations based on optical coherence tomography, the method comprising:

employing optical coherence tomography to measure light reflected from a patient's skin tissue at a plurality of depths;

determining a tissue scattering coefficient for a tissue region based on differences in light reflected at different depths;

detecting micro-oscillations in the tissue scattering coefficient over a time interval; and

relating the micro-oscillations to the patient's blood glucose concentrations.

2. The method of claim 1 , wherein the step of employing optical coherence tomography to measure reflected light further comprises obtaining a plurality of reflected light intensity measurements at varying tissue depths, each measurement obtained by interfering a tissue-reflected light beam with a reference-reflected light beam, the path length of the reference-reflected light beam determining a tissue depth for each measurement.

3. The method of claim 1 , wherein the step of determining a tissue scattering coefficient for a tissue region further comprises selecting a function that describes a relationship between reflected light measurements and their corresponding depths and applying the function to determine the scattering coefficient.

4. The method of claim 3 , wherein the function is a slope function.

5. The method of claim 1 , wherein the method further comprises detecting micro-oscillations having a period less than about 20 minutes.

6. The method of claim 1 , wherein the step of relating the micro-oscillations further comprises relating a period of the micro-oscillations to a patient's insulin response to blood glucose concentrations.

7. The method of claim 1 , wherein the step of relating the micro-oscillations further comprises relating an amplitude of the micro-oscillations to a patient's insulin response to blood glucose concentrations.

8. The method of claim 1 , wherein the patient has diabetes.

9. The method of claim 1 , wherein the step of relating the micro-oscillations further comprises relating the micro-oscillations with an insulin response in the patient.

10. The method of claim 1 , wherein the method further comprises providing a glucose sample to the patient.

11. The method of claim 10 , wherein the method further comprises relating a condition of the tissue with an impulse response due to the glucose sample.

12. The method of claim 1 , further comprising:

modulating insulin dosing in the patient such that micro-oscillations of the tissue scatter coefficient in the patient approach a normal micro-oscillation response to glucose dosing in a healthy patient.

13. The method of claim 1 , wherein the step of relating the micro-oscillations further comprises characterizing health of an organ or system of the patient based upon the detected micro-oscillations in the tissue scattering coefficient over the time interval.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: GLT ACQUISITION CORPORATION
To: MASIMO CORPORATION
Reel/Frame 041084/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: CERCACOR LABORATORIES, INC.
To: MASIMO CORPORATION
Reel/Frame 038049/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2010
From: GLUCOLIGHT CORPORATION
To: GLT ACQUISITION CORP.
Reel/Frame 024128/0642 →
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2009
From: HOUGHTON, ROBERT E.
To: GLUCOLIGHT CORP.
Reel/Frame 023660/0132 →
SECURITY AGREEMENT Recorded May 27, 2009
From: GLUCOLIGHT CORP.
To: HOUGHTON, ROBERT E.
Reel/Frame 022732/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2005
From: SCHURMAN, MATTHEW J.; SHAKESPEARE, WALTER JEFFREY
To: GLUCOLIGHT CORPORATION
Reel/Frame 016189/0532 →